Home > Partners

Academia Sinica

Academia Sinica, the most prestigious research institute in Taiwan has its campus within close proximity to TaiGen. Beginning in 2003, TaiGen has signed several collaborative agreements with the x-ray crystallography group at Academia Sinica for its drug discovery programs in antiviral and cancer fields. Under these agreements, Academia Sinica is responsible for developing the x-ray crystallography of drug lead/target protein complexes. The two parties have established an interactive and efficient collaboration structure; TaiGen provides funding for the research, while Academia Sinica in turn is entitled to receive payments when products from the collaboration are launched in the market.

Chang Gung Memorial Hospital

In the summer of 2002, TaiGen signed a collaborative agreement with Chang Gung Memorial Hospital (CGMH), the largest private hospital in Taiwan. Under the agreement, CGMH will make available to TaiGen hepatitis and cirrhotic liver tumor tissues from 7,000 cancer patients. TaiGen will conduct gene expressing profiling of these diseased tissues for drug target selection and validation. In 2004, TaiGen signed a second collaborative agreement with the hospital to conduct HCV drug screening by employing an in-vitro viral replication system developed by investigators at the hospital.

Zhejiang Medicine Company, Limited ("ZMC")

In June of 2012, TaiGen and Zhejiang Medicine Company, Limited ("ZMC") signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). ZMC is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries.


R-Pharm is a leading Russian pharmaceutical company with commercial operations in Russian Federation, CIS, and Turkey. In 2013, it has over 2800 employees with sales revenue of US$1.8 billion. Key business areas of R-Pharm include manufacturing, sales and marketing of prescription drugs, laboratory diagnostics, medical equipment, and venture investment.